Wanbury Ltd

Wanbury Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Wanbury Ltd

₹ 71.8 1.99%
04 Oct - close price
wanbury.com BSE: 524212 NSE - BE : WANBURY
About

Wanbury Ltd is primarily engaged in the manufacturing of APIs and marketing and trading of branded formulations[1][2]

Key Points

Product Portfolio
The company has two divisions API & Formulations.
APIs: The company has 13 products under its API segment which includes Metformin, Tramadol, Sertraline, Diphenhydramine Hcl, mefenamic acid, Promethazine, and others. It is also the largest manufacturer of Metformin with a capacity of 8,500 TPA.
Formulations: It sells ~70 products under various brands under this segment such as antibiotics, antiulcerants, pain management, neuropathic pain management, protein supplements, laxative, antiallergen, constipation, calcium supplement, and others. [1] [2]

Website BSE NSE - BE
  • Market Cap ₹ 232 Cr.
  • Current Price ₹ 71.8
  • High / Low ₹ 72.6 / 33.0
  • Stock P/E 109
  • Book Value ₹ -10.0
  • Dividend Yield 0.00 %
  • ROCE 20.8 %
  • ROE %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 6.19% over past five years.
  • Promoter holding is low: 39.8%
  • Contingent liabilities of Rs.907 Cr.
  • Promoters have pledged 76.7% of their holding.
  • Company's cost of borrowing seems high
  • Promoter holding has decreased over last 3 years: -12.3%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
67.16 95.21 109.70 120.45 127.86 124.09 124.84 134.39 116.94 123.96 125.78 132.98 146.29
70.12 86.23 95.94 122.21 121.32 116.99 115.99 121.58 119.99 118.36 119.33 118.83 132.94
Operating Profit -2.96 8.98 13.76 -1.76 6.54 7.10 8.85 12.81 -3.05 5.60 6.45 14.15 13.35
OPM % -4.41% 9.43% 12.54% -1.46% 5.11% 5.72% 7.09% 9.53% -2.61% 4.52% 5.13% 10.64% 9.13%
0.26 0.13 0.80 1.21 0.31 0.31 0.25 77.01 1.94 0.78 0.26 -2.65 0.62
Interest 6.05 5.02 6.21 5.79 5.02 5.16 5.64 4.79 3.31 3.94 6.63 7.51 5.79
Depreciation 2.37 2.40 2.39 2.59 2.64 2.78 3.03 3.00 3.03 3.15 3.13 3.07 3.18
Profit before tax -11.12 1.69 5.96 -8.93 -0.81 -0.53 0.43 82.03 -7.45 -0.71 -3.05 0.92 5.00
Tax % -0.36% 4.73% 0.84% -0.34% -7.41% -11.32% 13.95% -0.62% 2.82% -25.35% -7.54% -10.87% 6.00%
-11.16 1.60 5.91 -8.95 -0.86 -0.58 0.37 82.54 -7.24 -0.89 -3.28 1.02 4.69
EPS in Rs -4.46 0.64 2.36 -3.58 -0.26 -0.18 0.11 25.27 -2.21 -0.27 -1.00 0.31 1.43
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
386 459 661 250 420 432 370 391 367 392 511 500 529
388 491 637 228 387 414 438 375 344 374 475 476 489
Operating Profit -2 -32 25 21 33 19 -68 16 23 18 36 23 40
OPM % -1% -7% 4% 9% 8% 4% -18% 4% 6% 5% 7% 5% 7%
21 5 -78 6 0 90 76 9 84 2 77 0 -1
Interest 40 37 48 19 32 36 31 40 33 23 21 21 24
Depreciation 17 23 23 5 9 10 10 10 10 10 11 12 13
Profit before tax -39 -87 -125 4 -7 62 -32 -25 65 -12 81 -10 2
Tax % 0% -0% -2% 28% 0% 1% 1% 1% 0% -2% -0% -1%
-39 -87 -128 3 -7 62 -32 -25 64 -13 81 -10 2
EPS in Rs -22.38 -50.19 -63.95 1.60 -3.58 26.71 -13.49 -10.48 25.79 -5.04 24.94 -3.18 0.47
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 1%
5 Years: 6%
3 Years: 11%
TTM: 6%
Compounded Profit Growth
10 Years: 7%
5 Years: 11%
3 Years: 13%
TTM: 266%
Stock Price CAGR
10 Years: 13%
5 Years: 29%
3 Years: 29%
1 Year: 6%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
17 17 20 20 20 23 24 24 25 25 33 33
Reserves 27 -65 -212 -214 -209 -176 -208 -233 -168 -181 -56 -66
455 415 389 381 362 300 250 260 190 192 100 68
309 406 209 209 215 265 207 236 232 253 276 268
Total Liabilities 809 773 406 396 388 412 273 286 279 289 353 304
439 423 174 164 180 186 178 172 164 167 167 167
CWIP 17 25 13 19 14 10 10 9 14 11 2 2
Investments 1 1 0 0 0 0 0 0 0 0 0 0
352 324 219 213 193 216 84 105 101 111 183 135
Total Assets 809 773 406 396 388 412 273 286 279 289 353 304

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
9 87 68 40 43 43 32 30 44 17 41 20
-32 -21 -6 -5 -20 -13 -1 -3 64 8 1 -9
24 -64 -71 -30 -28 -27 -33 -27 -108 -17 -29 -32
Net Cash Flow 2 3 -9 5 -5 3 -2 -0 -0 7 13 -21

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 107 67 57 144 65 71 29 41 50 32 45 50
Inventory Days 113 63 42 103 69 63 27 36 25 41 60 27
Days Payable 159 114 113 301 172 260 174 209 253 221 233 179
Cash Conversion Cycle 61 15 -14 -55 -38 -125 -118 -131 -177 -148 -128 -103
Working Capital Days -165 -159 -3 -26 -45 -132 -195 -175 -212 -168 -103 -100
ROCE % -1% -11% 4% 12% 57% -1% 26% 31% 27% 46% 21%

Shareholding Pattern

Numbers in percentages

Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023
52.09% 52.09% 52.09% 39.90% 39.90% 39.89% 39.89% 39.85% 39.85% 39.84% 39.84% 39.84%
1.36% 1.13% 1.13% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
46.56% 46.78% 46.78% 60.09% 60.09% 60.11% 60.11% 60.15% 60.16% 60.16% 60.16% 60.16%
No. of Shareholders 12,56312,22911,83111,74811,58111,61911,28911,39811,55511,88811,91111,741

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings